HIGHLIGHTS
- who: Changjun Wang from the University of California San Francisco, San Francisco, CA, United States, State Key Laboratory of Medicinal Chemical have published the Article: Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis, in the Journal: (JOURNAL) of 21/03/2022
- what: The overall objective response rates (ORRs) of HDACi + ET (HE) and placebo + ET (PE) groups were 11.52% and 6.67%, respectively. Only the study by Jiang et_al used tucidinostat as HDACi while all the other trials focused on entinostat . Nine publications were considered to be . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.